Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
Heart of England NHS Foundation Trust · University of Birmingham · +3 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
575
total citations
- FWCI
- 43.03
- Percentile
- 100%
- References
- 36
Citations per year
Authors
7Topics & keywords
Topics
Keywords
- Medicine
- Empagliflozin
- Placebo
- Kidney disease
- Type 2 diabetes
- Internal medicine
- Clinical endpoint
- Diabetes mellitus
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.